MetaCap

Scilex (SCLX) vs VivoSim Labs (VIVS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

VivoSim Labs is the larger company by market cap ($5.3 million vs $4.0 million), about 1.3 times the size. Scilex converts more of its revenue into profit, with a net margin of -1236.4% versus -10567.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SCLX-83.79%VIVS+36.19%
+59%-16%-91%
Oct 7, 20261 yearNov 20, 2026
SCLX-80.62%VIVS+44.81%
+51%-18%-87%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SCLX versus VIVS key metrics
MetricSCLXVIVS
Share price$0.5658$0.2608
Market cap$3.98M$5.29M
1-day change-12.95%-10.53%
YTD return-92.55%—
1-year return-95.96%—
5-year return-99.74%—
Forward P/E0.78—
EPS (TTM)$-49.70$-3.41
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$30.25M$131.00K
Revenue growth (YoY)-46.54%-9.03%
Net income (latest FY)$-374.05M$-13.84M
Gross margin415.83%100.00%
Operating margin-1143.71%-8768.70%
Net margin-1236.42%-10567.18%
52-week high$14.34$3.40
52-week low$0.50$0.12
Distance from 52-week high-96.05%-92.33%
Average volume56.11K15.96M
Shares outstanding7.03M20.28M
Employees3415
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Scilex is more profitable, keeping -1236.4 cents of every revenue dollar as net income versus -10567.2 cents for VivoSim Labs.
  • VivoSim Labs grew revenue faster in its latest fiscal year (-9.03% vs -46.54%).

About Scilex

SCLX stock →

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees

About VivoSim Labs

VIVS stock →

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees

SCLX vs VIVS FAQ

Which is bigger, Scilex or VivoSim Labs?

VivoSim Labs (VIVS) is larger, with a market capitalization of $5.29M compared with $3.98M for Scilex (SCLX).

Are Scilex and VivoSim Labs in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons